GL1X · GenesisL1 explorer

Research workbench

Crystal structure of USP7 in complex with a 4-hydroxypiperidine based inhibitor

Analyse Crystal structure of USP7 in complex with a 4-hydroxypiperidine based inhibitor in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6F5H
Type
protein
Length
687 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Ubiquitin carboxyl-terminal hydrolase 7
EC
3.4.19.12
UniProt
Q93009
Ligands
CQ5, SO4
Pockets
11 · best druggability 0.73

Structure

x-ray diffraction · 2 distinct chains · 34% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AUbiquitin carboxyl-terminal hydrolase 7 (EC 3.4.19.12)protein35035% helix, 27% strandQ93009
BUbiquitin carboxyl-terminal hydrolase 7 (EC 3.4.19.12)protein33734% helix, 27% strandQ93009

Ligands and binding sites

  • CQ5 · 3-[[4-oxidanyl-1-[(3~{R})-3-phenylbutanoyl]piperidin-4-yl]methyl]-6-(2-pyrrolidin-1-ylethylamino)pyrimidin-4-one · ligand · 2 copies · chains A, B
  • SO4 · Sulfate ion · ion · 3 copies · chains A, B
  • GOL · Glycerol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

11 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11720.730.9022CQ5
21820.710.8925CQ5
31770.520.7826empty
41160.440.7722empty
51170.400.7519SO4

Interfaces

1 interface between chains.

  • A–B · 674 Ų buried · 6 hydrogen bonds · protein-protein

Compared structures

  • 6F5H · Crystal structure of USP7 in complex with a 4-hydroxypiperidine based inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.